Dr. Cristiano Resende

Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil ascopubs.org/doi/abs/10.120… Finally our paper was published at @JCOGO_ASCO. I’m very grateful for this opportunity.

Only few days to #ASCO26. For breast oncologists, this edition will deliver a new promising biomarker to spare unnecessary chemo, informative updates from practice-changing trials across subtypes, and major innovations coming from China. See you in Chicago next week! #bcsm

SG is a highly effective ADCs, and when used adequately, it saves lives. This includes careful management of toxicities, with prophylaxis when indicated. In this article we review the data & provide RW perspectives on the management of toxicities with SG. academic.oup.com/oncolo/advance…

It has been a big year for long-term follow up of adjuvant endocrine Rx in breast cancer. 1. Extended therapy. Overview shows AI treatment 5 -> 10 years lowers recurrence and distant recurrence. Esp in N+ and patients given tamoxifen in years 0-5. thelancet.com/journals/lance…

Multiple ADCs have outperformed chemo for treating mBC. Yet their most transformative impact is expected in the curative setting. DB11 will report at #ESMO25 & much more is coming. We review the field in our latest NPJ Breast review, led by Pooja Patel. nature.com/articles/s4152…

The CDK4/6i resistance setting remains one of the most complex and rapidly evolving challenges in HR+/HER2- advanced breast cancer. I’m pleased to share our newly published review, covering: (1/5)

Convite para o Tumor Board do GBECAM Temos o prazer de convidá-los para o Tumor Board do GBECAM, um evento dedicado à discussão multidisciplinar de casos em oncologia mamária. Esta iniciativa visa promover a colaboração entre especialistas para otimizar a tomada de decisões e proporcionar o melhor cuidado aos pacientes. Detalhes do evento: 📌 Tema: Decisões de tratamento baseadas em painel genômico (ou na ausência dele) 📅 Data: 22/04/2025 (Terça-feira) ⏰ Horário: 19:00 - 20:30 (BRT) 🔗 Via Zoom Coordenação: 🔹 Dra. Solange Sanches – Oncologista (SP) @DraSSanches 🔹 Dr. Cristiano Resende – Oncologista (DF) @crisonco Moderação: 🔹 Dra. Martina Arenhardt @mparenhardt Debatedores: 🔹 Dr. Francisco Pimentel – Mastologista (CE) 🔹 Dr. Leandro Jonata – Oncologista (SP) @LeandroJonatad1 🔹 Dr. Gustavo Nader – Radioterapeuta (SP) 🔹 Dra. Ruana Rocha – Patologista (CE) @RuanaRocha 🔗Acesse o link para se inscrever us02web.zoom.us/webinar/regist…

We have good evidence that leaving lymph nodes behind does not necessarily compromise outcomes. Could we push the limit & leave the tumor unresected in some responders? Early days, but fascinating concept. Congrats to the authors for this important report! jamanetwork.com/journals/jamao…

According to this study, the survival outcomes of the ER-intermediate group are worse than those of the ER-high group and resemble those of the ER-negative and ER-low groups. While the study has several limitations, the conventional IHC method may lead to both overtreatment and undertreatment in many patients. In an era of significant technological advancements, classifying patients based on stratifications established 40–50 years ago appears to be inadequate. esmoopen.com/article/S2059-…

Why does T-DXd work so well even in HER2-0 tumors? Nice preclinical work, demonstrating that the activity of T-DXd in HER2- breast cancer mostly relies on extracellular release of the payload by cathepsins, rather than ADC internalization. ADCs are complex, fascinating molecules.

Published in @JNCI_Now our analysis assessing the prognosis of patients considered at high risk of recurrence according to #monarchE and #NATALEE trials inclusion criteria! 📄: #google_vignette" target="_blank" rel="nofollow noopener">academic.oup.com/jnci/advance-a… @BlondeauxEva @matteolambe @delmastro_lucia @OncoAlert Main findings here👇🏼

The #SERENA6 phase 3 trial is positive: a switch to camizestrant + CDK4/6i (vs continuation of AI + CDK4/6i) upon emergence of ESR1 mutations led to a significant improvement in PFS. PFS2 and OS, which will be key to interpret the results, remain immature. astrazeneca.com/media-centre/p…

Presented at #ASCO24 and now out in @JCO_ASCO results of our study on clinical behavior of #BreastCancer in young #BRCA carriers and importance of prediagnostic awareness of germline BRCA status..grateful to all #BRCABCYcollaboration #bcsm @OncoAlert Link: ascopubs.org/doi/pdf/10.120…

Interesting commentary on one of the most relevant and debated recent studies in breast oncology: SONIA. Are the results compelling enough to consider a delayed administration of CDK4/6-inhibitors for HR+/HER2- MBC? nature.com/articles/s4157…

SERENA-6: ctDNA guided approach to switching from AI to camizestrant upon development of ESR1m in combo with cdk4/6i demonstrates improvement in PFS! PFS2 + OS immature Could be a paradigm shift + could introduce ctDNA monitoring into practice astrazeneca.com/media-centre/p…

🔥🚨HOT OFF THE PRESS Just published @JCO_ASCO IMPORTANT SPECIAL ARTICLE & #Recommendations for #Academic #MedicalCenters by @ASCO on: Promoting Reasonable #CareerExpectations & Maximizing Professional Fulfillment for #Academic #Oncologists PLZ SHARE👇🏻 ascopubs.org/doi/10.1200/JC…

@GuiNaderMarta @OncoAlert @DFCI_BreastOnc Excellent paper. Congratulations!

If you’re interested in the topic, don’t miss our full review on the current role of #anthracyclines in early breast cancer treatment We analyze efficacy, toxicity & pt selection, including data recently presented on the predictive value of #Oncotype & #MammaPrint @OncoAlert

Otto Metzger (@Otto_DFCI) presents the practice-changing results from the #PATINA phase 3 trial: adding palbociclib to maintenance ET after 1L THP for HR+/HER2+ MBC significantly and meaningfully improved PFS (44 vs 29 months, HR 0.74, p=0.007). 44 months!!!!!!!!!!!!!!!!!!!!!!!!

Unprecedented outcomes in 1L HER2+ BC! It is amazing to see this improvement for ER+ HER2+ BC! Practice changing data! @Otto_DFCI @DFCI_BreastOnc

New research recently published in @NatureMedicine showcases a multi-modal single-cell and spatial expression map of #MetastaticBreastCancer biopsies across clinicopathological features. Check it out here: 🔓pubmed.ncbi.nlm.nih.gov/39478111/ ✍️@DrDAbravanel @D_R_Goodwin @mor_nitzan @juliaawaldman @jgtzanudo @nlinmd @stolaney1 @DrEricWiner @eboyden3 @GarryPNolan @Nikhilwagle #BreastCancer #TumorMicroenvironment